We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Influence of SISCOM on Intracranial Electrode Implantation in Epilepsy Surgical Candidates

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00587951
Recruitment Status : Completed
First Posted : January 8, 2008
Last Update Posted : January 8, 2008
Information provided by:
Mayo Clinic

December 22, 2007
January 8, 2008
January 8, 2008
December 2005
February 2007   (Final data collection date for primary outcome measure)
Category of management recommendation (proceed straight to surgical resection, intracranial electrode implantation, more imaging studies OR recommend medical rather than surgical management) [ Time Frame: Instantaneous ]
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
The Influence of SISCOM on Intracranial Electrode Implantation in Epilepsy Surgical Candidates
The Influence of SISCOM on Intracranial Electrode Implantation in Epilepsy Surgical Candidates

The aim of this study is to determine the role of SISCOM (see below) in aiding clinicians to manage epilepsy surgery candidates. SISCOM is already a routine component of pre-surgical epilepsy evaluation at Mayo Clinic. In particular, we are interested in assessing whether use of SISCOM can minimize the need for prolonged (>24 hours) invasive monitoring with electrodes placed on the surface of the brain prior to surgical resection.

Note: this study has recruited the required number of patients and is closed to further enrolment.

Successful epilepsy surgery depends on accurate identification of the area of brain from which seizures originate (the epileptogenic zone). There are many non-invasive tests (including EEG and MRI) to indicate this area. Some patients require implantation of intracranial electrodes in order to determine the epileptogenic zone. A test known as SISCOM (subtraction ictal-interictal SPECT co-registered with MRI) has been validated as a non-invasive means of indicating the epileptogenic zone. However, this test is not widely available in the US, and it is not known how often the additional information provided by SISCOM makes a difference to clinical decision-making.

In order to determine the contribution of SISCOM towards clinical decision-making in epilepsy surgery candidates, we will ask epileptologists at Mayo Clinic to consider case presentations given all clinical information except for SISCOM results, and then to reconsider those same cases in conjunction with SISCOM data. This will indicate the degree to which SISCOM influences decision making.

50 patients at Mayo Clinic (38 adults, 12 children) will be enrolled.

Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Patients evaluated at Mayo Clinic and being considered for epilepsy surgery.
Not Provided
Candidates for epilepsy surgery, undergoing pre-surgical evaluation at Mayo Clinic, and in whom SISCOM was ordered by the treating physician as part of that evaluation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
February 2007
February 2007   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of localization-related epilepsy
  • Evaluated by clinical epileptologist at Mayo Clinic
  • SISCOM ordered by treating physician
  • Case presented at weekly Epilepsy Surgery Conference
  • Patient consent
Sexes Eligible for Study: All
Child, Adult, Senior
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Dr. K. Meng Tan, Mayo Foundation
Mayo Clinic
Not Provided
Principal Investigator: Meng Tan, MD Mayo Clinic
Mayo Clinic
November 2007